BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22237383)

  • 21. Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study.
    Greggi S; Mangili G; Scaffa C; Scala F; Losito S; Iodice F; Pisano C; Montoli S; Viganò R; Pirozzi G; Giannarelli D
    Int J Gynecol Cancer; 2011 May; 21(4):661-7. PubMed ID: 21412164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome.
    Faratian D; Stillie A; Busby-Earle RM; Cowie VJ; Monaghan H
    Int J Gynecol Cancer; 2006; 16(3):972-8. PubMed ID: 16803471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.
    Kelly MG; O'Malley D; Hui P; McAlpine J; Dziura J; Rutherford TJ; Azodi M; Chambers SK; Schwartz PE
    Gynecol Oncol; 2004 Dec; 95(3):469-73. PubMed ID: 15581948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006.
    Tchabo NE; McCloskey S; Mashtare TL; Andrews C; Singh AK; Mhawech-Fauceglia P; Odunsi K; Lele S; Jaggernauth W
    Gynecol Oncol; 2009 Nov; 115(2):249-56. PubMed ID: 19692115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant Pelvic Radiation Therapy±Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid Carcinoma.
    Nagar H; Yan W; Parashar B; Nori D; Chao KS; Christos P; Gupta D; Holcomb K; Caputo T; Wernicke AG
    Am J Clin Oncol; 2016 Aug; 39(4):335-9. PubMed ID: 27028349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma.
    Gupta D; Gunter MJ; Yang K; Lee S; Zuckerwise L; Chen LM; Goldberg GL; Huang GS
    Int J Gynecol Cancer; 2011 Apr; 21(3):529-34. PubMed ID: 21436701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma.
    Thomas MB; Mariani A; Cliby WA; Keeney GA; Podratz KC; Dowdy SC
    Gynecol Oncol; 2007 Nov; 107(2):186-9. PubMed ID: 17688926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uterine papillary serous carcinoma pre-operatively diagnosed as endometrioid carcinoma: Is omentectomy necessary?
    Peled Y; Aviram A; Krissi H; Gershoni A; Sabah G; Levavi H; Eitan R
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):498-502. PubMed ID: 26235227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).
    Fader AN; Starks D; Gehrig PA; Secord AA; Frasure HE; O'Malley DM; Tuller ER; Rose PG; Havrilesky LJ; Moore KN; Huh WK; Axtell AE; Kelley JL; Zanotti KM;
    Gynecol Oncol; 2009 Nov; 115(2):244-8. PubMed ID: 19712966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Adjuvant Therapy for Stage IA Serous and Clear Cell Uterine Cancer: Is Observation a Valid Strategy?
    Velker V; D'Souza D; Prefontaine M; McGee J; Leung E
    Int J Gynecol Cancer; 2016 Mar; 26(3):491-6. PubMed ID: 26825823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival after pelvic exenteration for uterine malignancy: A National Cancer Data Base study.
    Seagle BL; Dayno M; Strohl AE; Graves S; Nieves-Neira W; Shahabi S
    Gynecol Oncol; 2016 Dec; 143(3):472-478. PubMed ID: 27760707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
    Kelly MG; O'malley DM; Hui P; McAlpine J; Yu H; Rutherford TJ; Azodi M; Schwartz PE
    Gynecol Oncol; 2005 Sep; 98(3):353-9. PubMed ID: 16005947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes of adjuvant chemotherapy and vaginal brachytherapy with or without pelvic radiation for surgical stage I-II uterine serous carcinoma.
    Robbins JR; Siddiqui MS; Al-Wahab Z; Laser B; Lu M; Ali-Fehmi R; Munkarah A; Elshaikh MA
    Eur J Gynaecol Oncol; 2012; 33(5):449-54. PubMed ID: 23185785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extrauterine Spread, Adjuvant Treatment, and Prognosis in Noninvasive Uterine Papillary Serous Carcinoma of the Endometrium: A Retrospective Multicenter Study.
    Boyraz G; Salman MC; Basaran D; Ozgul N; Turan T; Turkmen O; Kimyon GC; Ozkan NT; Cagan M; Gungor T; Meydanli MM; Gungorduk K; Gulseren V; Sanci M; Yuce K
    Int J Gynecol Cancer; 2017 Jan; 27(1):102-108. PubMed ID: 27668395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
    Ma SK; Zhang HT; Sun YC; Wu LY
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.
    Vogel TJ; Knickerbocker A; Shah CA; Schiff MA; Isacson C; Garcia RL; Goff BA
    J Gynecol Oncol; 2015 Jan; 26(1):25-31. PubMed ID: 25376917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of clinical and pathological characteristics, treatment methods, survival, and prognosis of uterine papillary serous carcinoma.
    Solmaz U; Ekin A; Mat E; Gezer C; Dogan A; Biler A; Peker N; Hasdemir PS; Sanci M
    Tumori; 2016 Dec; 102(6):593-599. PubMed ID: 27514313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994.
    Craighead PS; Sait K; Stuart GC; Arthur K; Nation J; Duggan M; Guo D
    Gynecol Oncol; 2000 May; 77(2):248-53. PubMed ID: 10785473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uterine serous carcinoma: a historic evaluation of therapy.
    de Leeuw Fa; Rijcken Fe; Trum Jw; van der Noort V; Tjon-Kon-Fat Ri; Bleeker Mc; Kenter Gg
    Eur J Gynaecol Oncol; 2016; 37(2):211-5. PubMed ID: 27172747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study.
    Mahdi H; Rose PG; Elshaikh MA; Munkarah A; Isrow D; Singh S; Waggoner S; Ali-Fehmi R; Morris RT; Harding J; DeBenardo R
    Gynecol Oncol; 2015 Mar; 136(3):529-33. PubMed ID: 25575483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.